Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. director Harry Jr Penner reported receiving a grant of non-qualified stock options. The award covers 26,000 options to buy Celldex common stock at an exercise price of $34.09 per share, expiring on June 25, 2036. The options, issued at no cost to the director, were granted under the company’s 2021 Omnibus Equity Incentive Plan and leave him holding 26,000 derivative securities following the transaction. This is a compensation-related grant rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PENNER HARRY JR

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	26,000	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 26,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 26,000 options Exercise price: $34.09 per share Expiration date: June 25, 2036 +2 more

5 metrics

Options granted 26,000 options Non-qualified stock options granted to director

Exercise price $34.09 per share Strike price of granted options

Expiration date June 25, 2036 Option expiration

Cost of grant $0.00 per option Options granted at no upfront cost

Derivative holdings after grant 26,000 options Total derivative securities following transaction

Key Terms

Non-Qualified Stock Option, 2021 Omnibus Equity Incentive Plan, grant/award acquisition, exercise price, +1 more

5 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 34.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"total_shares_following_transaction: 26000.0000"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:07 PM Accepted by SEC EDGAR 06/29/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PENNER HARRY JR

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		26,000		06/25/2027	06/25/2036	Common Stock	26,000	$0	26,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

	/s/ Sam Martin, attorney-in-fact for Harry H. Penner, Jr.	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Celldex (CLDX) director Harry Jr Penner report in this Form 4?

Harry Jr Penner reported receiving a grant of 26,000 non-qualified stock options in Celldex. These options give him the right to buy common shares at a fixed price, reflecting equity-based compensation rather than an open-market transaction.

How many Celldex (CLDX) options were granted to the director and at what price?

The director was granted 26,000 non-qualified stock options with an exercise price of $34.09 per share. This strike price is the cost per share he must pay to convert each option into Celldex common stock in the future.

When do Harry Jr Penner’s Celldex (CLDX) stock options expire?

The 26,000 non-qualified stock options granted to Harry Jr Penner expire on June 25, 2036. After this expiration date, any unexercised options will lapse and no longer give him the right to purchase Celldex common shares.

Is the Celldex (CLDX) Form 4 a stock purchase or sale by the director?

The Form 4 reflects a grant of stock options, not a market purchase or sale. It is classified as a grant or award acquisition, meaning the director received options as compensation rather than buying or selling existing Celldex shares in the open market.

Under which plan were the Celldex (CLDX) options granted to the director?

The 26,000 stock options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan authorizes the company to issue equity-based awards, such as options, to directors and employees as part of their overall compensation package.

How many derivative securities does the Celldex (CLDX) director hold after this grant?

Following the grant, the director holds 26,000 derivative securities in the form of non-qualified stock options. This entire position comes from the new award, and reflects his potential future right to acquire Celldex common stock at the set exercise price.